Gout Flare
23
4
5
9
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.7%
2 terminated out of 23 trials
81.8%
-4.7% vs benchmark
17%
4 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (23)
Serum Potassium Prediction Using Machine Learning and Single-lead ECG
Prediction of Expected Length of Hospital Stay Using Machine Learning
Prediction of 30-Day Readmission Using Machine Learning
Home Hospital for Suddenly Ill Adults
Prediction of Patient Deterioration Using Machine Learning
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
Rural Hospital-Level Care at Home for Acutely Ill Adults
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
Developing A Gout Action Plan in Primary Care Setting in Singapore
Rural Home Hospital: Proof of Concept
Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare
The Effect of Tart Cherry Juice on Risk of Gout Attacks
Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare
Distribution of Immune Cells and Their Subtypes in Peripheral Blood of Gout
Treatment of Topical Ketorolac Gel in Acute Gouty Flare
The Effects of Limb Elevation During Gout Flare Episodes
Novel Biomarkers for Early Renal Injury in Children With Sepsis